SCHEMBL762871

SCHEMBL762871

Cn1nc(N)c2cc(C(=O)OC(C)(C)C)sc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.52
PKM P14618 1/20 0.52
PIM3 Q86V86 1/20 0.49
PIM2 Q9P1W9 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.46
ALDH1A1 P00352 7/20 0.42
KDM4E B2RXH2 7/20 0.42
HSD17B10 Q99714 3/20 0.40
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 3/20 0.39
HPGD P15428 2/20 0.39
GAA P10253 3/20 0.39
MAPT P10636 5/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
NPSR1 Q6W5P4 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.36
LMNA P02545 1/20 0.35
APEX1 P27695 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13685824 0.86 NPC1 (0.65) NPC1PKMPIM3PIM2L3MBTL1
SCHEMBL13685826 0.82 KDM4E (0.56) NPC1PKMPIM3PIM2L3MBTL1
SCHEMBL742358 0.80 KDM4E (0.43) NPC1PKMPIM3PIM2L3MBTL1
SCHEMBL762815 0.78 NPC1 (0.40) NPC1PKMPIM3PIM2L3MBTL1
SCHEMBL742663 0.71 CSNK2A2 (0.40) ALDH1A1LMNA
SCHEMBL13685825 0.69 NPC1 (0.65) NPC1PKMPIM3PIM2L3MBTL1
SCHEMBL27244031 0.69 KDM4E (0.76) NPC1PKMALDH1A1KDM4EHSD17B10
SCHEMBL17796531 0.67 KDM4E (0.40) NPC1PKMALDH1A1KDM4ECYP2C19
SCHEMBL12895643 0.66 KDM4E (0.56) NPC1PKMPIM3PIM2L3MBTL1
SCHEMBL1668058 0.65 NPC1 (0.71) NPC1PKMPIM3PIM2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481584-B2 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-07-09 US disclosed
US-20120165311-A1 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-06-28 US disclosed
US-8138217-B2 Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165311-A1 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K3 NPC1 3113/4885PKM 320/4885PIM3 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.